When Do You See Weight Loss on Wegovy? A Comprehensive Guide

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The honest answer is that the timeline in the published trials is far longer than most people expect, and the headline number belongs to the end of it, not the beginning. In STEP 1, the pivotal 68-week trial that supported Wegovy's weight-management approval, the mean change in body weight from baseline was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. That figure was measured at week 68 — roughly sixteen months. Weight began coming off well before then, and the trial record gives us a reasonable picture of the intermediate milestones, but the curve in these studies keeps descending for the better part of a year before it flattens. Anyone judging the medication at week six is reading the first chapter of a long book.

What the Pivotal Trial Actually Measured

STEP 1 enrolled 1,961 adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related coexisting condition, none of whom had diabetes. Participants were randomized 2:1 to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo, both alongside lifestyle intervention. The coprimary endpoints were percentage change in body weight and achieving at least a 5% reduction.

The absolute numbers matter as much as the percentages. Mean weight change was −15.3 kg with semaglutide versus −2.6 kg with placebo, an estimated treatment difference of −12.7 kg. Response rates at week 68 were 86.4% for at least 5% loss, 69.1% for at least 10%, and 50.5% for at least 15%, compared with 31.5%, 12.0% and 4.9% respectively on placebo. Those are endpoint measurements, not month-three measurements.

The 20-Week Mark: What the Record Shows

A second trial gives an unusually clean read on the early period. STEP 4 was designed as a randomized withdrawal study: every participant first received open-label semaglutide during a 20-week run-in, and only those who completed it were randomized. Across that run-in, participants achieved a mean weight reduction of 10.6%.

That single figure is the most useful anchor available for the "how long until I see something" question. Roughly five months in, the average participant in a controlled trial setting had lost about a tenth of their starting weight — meaningful, visible, and still only about two-thirds of the way to the 68-week average. The trajectory is real and it is gradual.

Escalation Is Built Into the Timeline

Part of why the early weeks look modest is that nobody starts at the maintenance dosage. The Wegovy prescribing information describes a stepwise escalation: treatment is initiated at a low starting dosage and increased at intervals until the maintenance dosage is reached. That schedule exists for tolerability, not for efficacy, and it means the first stretch of treatment is spent at doses below the ones that produced the trial results.

Pharmacology reinforces the same point. Semaglutide reaches maximum plasma concentration one to three days after a dose and has an elimination half-life of approximately one week, which is what makes once-weekly administration workable — but it also means concentrations build over several weeks rather than arriving with the first injection. The exact escalation applied to any individual is a decision for the prescriber, documented on the pharmacy label that comes with the medication.

Why the Curve Keeps Descending Past Month Six

Obesity pharmacotherapy trials are long for a reason: the weight-loss curve in this drug class does not plateau early. STEP 1 ran to week 68. The trial supporting Wegovy's higher-dose presentation ran 72 weeks in 1,407 participants and reported −18.7% with semaglutide 7.2 mg versus −15.6% with 2.4 mg and −3.9% with placebo — results that led to the approval of the 7.2 mg maximum maintenance dosage now reflected in the labeling. Comparable programs for other molecules use the same horizon; SURMOUNT-1, the 72-week tirzepatide obesity trial in 2,539 adults, reported −15.0%, −19.5% and −20.9% across doses versus −3.1% with placebo.

The practical implication is that a plateau at month four is not necessarily a plateau at all. It may simply be a point on a curve that has more room in it. Whether that is true for a given person is a clinical judgment, not something a chart of averages can settle.

Averages Describe Groups, Not People

Roughly one in seven STEP 1 participants on semaglutide did not reach even a 5% reduction by week 68, and half did not reach 15%. Meanwhile some placebo participants lost weight. Response varies widely, and the reasons include baseline metabolic status, adherence, concurrent medications, sleep, activity and diet — most of which are not captured in a summary statistic.

Day-to-day scale readings are also noisier than the underlying change. Fluid shifts, sodium intake, glycogen and menstrual-cycle timing can move body weight by a kilogram or more in either direction within a week, which is why trials report means over long intervals rather than weekly readouts. A four-week trend line is more informative than any single morning.

What Is Worth Tracking, and When to Raise It

Weight is the endpoint most people watch, but it is not the only signal. STEP 1 reported greater improvement in cardiometabolic risk factors and in participant-reported physical functioning with semaglutide, and STEP 4 reported reductions in waist circumference of 9.7 cm and systolic blood pressure of 3.9 mm Hg versus placebo over the randomized period. Waist measurement, blood pressure, and lipid and glycemic labs frequently move before the scale tells a convincing story.

STEP 4 also demonstrated what happens when treatment stops. Participants switched to placebo after the run-in regained, with a body weight change of +6.9% from week 20 to week 68, versus −7.9% in those who continued. Obesity behaves as a chronic condition in these trials, and the timeline question is therefore less "when do I see results" than "what does long-term management look like." If progress stalls, or if gastrointestinal side effects are interfering with eating, that is a conversation for the prescriber rather than a reason to guess.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How long did it take to reach the headline weight loss in the Wegovy trial?

STEP 1 measured its primary endpoint at week 68, about sixteen months. At that point the mean change in body weight was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo, an estimated treatment difference of −12.4 percentage points. In absolute terms that was −15.3 kg versus −2.6 kg. The −14.9% figure describes the end of the trial, not an early milestone, so comparing an early result against it is misleading.

Is there any published figure for the first few months?

Yes. STEP 4 used a 20-week open-label run-in before randomization, and participants achieved a mean weight reduction of 10.6% across that run-in period. That is the cleanest published anchor for the roughly five-month mark. It is a trial-setting average with structured lifestyle support, so individual experience outside a trial can differ substantially in both directions.

Why is weight loss slower at the start of treatment?

Two reasons. The Wegovy labeling describes a stepwise dosage escalation, so the earliest weeks are spent below the maintenance dosage that generated the trial results. And semaglutide has an elimination half-life of approximately one week, meaning plasma concentrations accumulate over multiple doses rather than arriving immediately. The specific escalation applied to any individual comes from the prescriber and the pharmacy label.

What should I do if my weight stalls after a few months?

Bring it to your prescriber rather than adjusting anything yourself. A stall at month four is not necessarily a true plateau, since the pivotal trials ran 68 to 72 weeks and the average curve continued descending well past the halfway point. Your prescriber can review adherence, other medications, tolerability, and whether measurements other than body weight are moving before deciding what, if anything, should change.

Does weight come back if the medication is stopped?

In STEP 4 it did. After a 20-week run-in, participants randomized to placebo had a body weight change of +6.9% from week 20 to week 68, while those who continued semaglutide changed −7.9%, a difference of −14.8 percentage points. That trial is the main published evidence that these medications treat obesity as an ongoing condition rather than delivering a one-time correction. Any decision about stopping belongs with your prescriber.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.